211 related articles for article (PubMed ID: 23035730)
1. What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trial.
Tinelli M; Ozolins M; Bath-Hextall F; Williams HC
BMC Dermatol; 2012 Oct; 12():19. PubMed ID: 23035730
[TBL] [Abstract][Full Text] [Related]
2. The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma.
Ozolins M; Williams HC; Armstrong SJ; Bath-Hextall FJ
Trials; 2010 Apr; 11():42. PubMed ID: 20409337
[TBL] [Abstract][Full Text] [Related]
3. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial.
Bath-Hextall F; Ozolins M; Armstrong SJ; Colver GB; Perkins W; Miller PS; Williams HC;
Lancet Oncol; 2014 Jan; 15(1):96-105. PubMed ID: 24332516
[TBL] [Abstract][Full Text] [Related]
4. Treatment of cutaneous tumors with topical 5% imiquimod cream.
Alessi SS; Sanches JA; Oliveira WR; Messina MC; Pimentel ER; Festa Neto C
Clinics (Sao Paulo); 2009; 64(10):961-6. PubMed ID: 19841702
[TBL] [Abstract][Full Text] [Related]
5. Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study.
van der Geer S; Martens J; van Roij J; Brand E; Ostertag JU; Verhaegh ME; Neumann HA; Krekels GA
Br J Dermatol; 2012 Jul; 167(1):110-5. PubMed ID: 22385074
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome after treatment with 5% topical imiquimod cream in patients with basal cell carcinoma of the eyelids.
Prokosch V; Thanos S; Spaniol K; Stupp T
Graefes Arch Clin Exp Ophthalmol; 2011 Jan; 249(1):121-5. PubMed ID: 20886224
[TBL] [Abstract][Full Text] [Related]
7. Patient preferences for curettage followed by imiquimod 5% cream vs. surgical excision for the treatment of non-facial nodular basal cell carcinoma: a discrete choice experiment.
Sinx KAE; Mosterd K; de Coster D; Essers BA
J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):e41-e43. PubMed ID: 34416061
[No Abstract] [Full Text] [Related]
8. Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma.
Bostanci S; Kocyigit P; Vural S; Heper AO; Botsali A
Dermatol Surg; 2018 Jan; 44(1):36-41. PubMed ID: 29016542
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens.
Shumack S; Robinson J; Kossard S; Golitz L; Greenway H; Schroeter A; Andres K; Amies M; Owens M
Arch Dermatol; 2002 Sep; 138(9):1165-71. PubMed ID: 12224977
[TBL] [Abstract][Full Text] [Related]
10. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
[TBL] [Abstract][Full Text] [Related]
11. Surgery Versus 5% Imiquimod for Nodular and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS Randomized Controlled Trial.
Williams HC; Bath-Hextall F; Ozolins M; Armstrong SJ; Colver GB; Perkins W; Miller PSJ;
J Invest Dermatol; 2017 Mar; 137(3):614-619. PubMed ID: 27932240
[TBL] [Abstract][Full Text] [Related]
12. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion.
Sterry W; Ruzicka T; Herrera E; Takwale A; Bichel J; Andres K; Ding L; Thissen MR
Br J Dermatol; 2002 Dec; 147(6):1227-36. PubMed ID: 12452875
[TBL] [Abstract][Full Text] [Related]
13. Treatment of facial superficial basal cell carcinomas with imiquimod 5% cream.
Mirza B; De'Ambrosis B
Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():16-8. PubMed ID: 14616806
[TBL] [Abstract][Full Text] [Related]
14. Imiquimod: a review of basal cell carcinoma treatments.
Karve SJ; Feldman SR; Yentzer BA; Pearce DJ; Balkrishnan R
J Drugs Dermatol; 2008 Nov; 7(11):1044-51. PubMed ID: 19110735
[TBL] [Abstract][Full Text] [Related]
15. [Alternative to surgery in basal cell carcinoma in the elderly population: imiquimod 5% cream].
Arias Santiago SA; Ruiz Villaverde R; Burkhardt Pérez P; Naranjo Sintes R
Rev Esp Geriatr Gerontol; 2009; 44(2):94-7. PubMed ID: 19285364
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of treatment of superficial basal cell carcinoma: surgical excision vs. imiquimod 5% cream.
Vanaclocha F; Daudén E; Badía X; Guillén C; Conejo-Mir JS; Sainz de Los Terreros M; Hamel L; Llorens MA;
Br J Dermatol; 2007 Apr; 156(4):769-71. PubMed ID: 17263811
[No Abstract] [Full Text] [Related]
17. Imiquimod 5% Cream as Adjuvant Therapy in BCC Treatment Located at High-Risk Regions.
Cengiz FP; Kelahmetoglu O; Emiroglu N; Onsun N
J Cutan Med Surg; 2020; 24(6):640-641. PubMed ID: 32558591
[No Abstract] [Full Text] [Related]
18. Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series.
Huber A; Huber JD; Skinner RB; Kuwahara RT; Haque R; Amonette RA
Dermatol Surg; 2004 Mar; 30(3):429-30. PubMed ID: 15008876
[TBL] [Abstract][Full Text] [Related]
19. Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.
Tillman DK; Carroll MT
Cutis; 2007 Mar; 79(3):241-8. PubMed ID: 17674590
[TBL] [Abstract][Full Text] [Related]
20. Has imiquimod 5% cream a role in the management of recurrent basal cell carcinoma?
RUIZ-VILLAVERDE R; SANCHEZ-CANO D; BURKHARDT-PEREZ P; SINTES RN
Eur J Dermatol; 2009; 19(5):481-3. PubMed ID: 19527989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
